Skip to main content

Iovance Biotherapeutics, Inc.

IOVA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001425205

No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.

Holders of 5% or more of IOVA

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Iovance Biotherapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of IOVA
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A7.50%33.4M shares+1.10 ppfrom 6.40%Jul 17, 20252 filingsJul 28, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

44 Schedule 13D and 13G filings on Iovance Biotherapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on IOVA
Filed (ET)FilerFormStakeChangeEvent dateFiling
Nov 10, 20268:22 AM ETState Street Corp13G4.80%21.7M shares−0.70 ppfrom 5.50%Below 5%Sep 30, 2026SEC
Aug 7, 20269:56 AM ETState Street Corp13G5.50%24.5M shares+1.30 ppfrom 4.20%Jun 30, 2026SEC
Jul 28, 20264:44 PM ETBlackRock, Inc.13G/A7.50%33.4M shares+1.10 ppfrom 6.40%Jun 30, 2026SEC
May 12, 202611:17 AM ETState Street Corp13G4.20%17.4M shares−0.90 ppfrom 5.10%Below 5%Mar 31, 2026SEC
Mar 27, 20269:52 AM ETVanguard Group Inc13G/A0.00%0 shares−7.50 ppfrom 7.50%Below 5%Mar 13, 2026SEC
Feb 9, 20266:43 AM ETState Street Corp13G5.10%20.2M shares–Dec 31, 2025SEC
Jul 29, 20251:46 PM ETVanguard Group Inc13G/A7.50%25.1M shares–Jun 30, 2025SEC
Jul 17, 20258:12 PM ETBlackRock, Inc.13G/A6.40%21.3M shares–Jun 30, 2025SEC
May 15, 20254:30 PM ETPerceptive Advisors LLCand 2 others13G/A3.80%12.8M shares−3.50 ppfrom 7.30%Below 5%Mar 31, 2025SEC
Feb 14, 20254:15 PM ETPerceptive Advisors LLCand 2 others13G/A7.30%22.1M shares–Dec 31, 2024SEC
Nov 14, 2024Perceptive Advisors LLC13G/AOld format–––SEC
Oct 18, 2024State Street Corp13G/AOld format–––SEC
Mar 19, 2024Quogue Capital LLC13D/AOld format–––SEC
Mar 1, 2024Perceptive Advisors LLC13GOld format–––SEC
Feb 14, 2024Perceptive Advisors LLC13G/AOld format–––SEC
Feb 14, 2024Point72 Asset Management, L.P.13G/AOld format–––SEC
Feb 13, 2024Vanguard Group Inc13G/AOld format–––SEC
Feb 9, 2024MHR Fund Management LLC13G/AOld format–––SEC
Jan 26, 202411:49 AM ETBlackRock Inc.13G/AOld format–––SEC
Jan 25, 2024State Street Corp13G/AOld format–––SEC
Oct 27, 2023Quogue Capital LLC13D/AOld format–––SEC
Feb 17, 2023Point72 Asset Management, L.P.13GOld format–New–SEC
Feb 14, 2023Perceptive Advisors LLC13G/AOld format–––SEC
Feb 14, 2023Avoro Capital Advisors LLC13G/AOld format–––SEC
Feb 9, 2023Vanguard Group Inc13G/AOld format–––SEC
Feb 6, 2023Wellington Management Group LLP13G/AOld format–––SEC
Feb 3, 202312:10 PM ETBlackRock Inc.13GOld format–––SEC
Feb 2, 2023State Street Corp13GOld format–New–SEC
Jan 13, 2023Quogue Capital LLC13D/AOld format–––SEC
Dec 30, 2022MHR Fund Management LLC13GOld format–New–SEC
Feb 24, 20225:23 PM ETBlackRock Inc.13G/AOld format–––SEC
Feb 14, 2022Perceptive Advisors LLC13G/AOld format–––SEC
Feb 14, 2022Price T Rowe Associates Inc13G/AOld format–––SEC
Feb 11, 2022Avoro Capital Advisors LLC13G/AOld format–––SEC
Feb 10, 2022Vanguard Group Inc13G/AOld format–––SEC
Feb 4, 2022Wellington Management Group LLP13GOld format–New–SEC
Feb 4, 2022Franklin Resources Inc13G/AOld format–––SEC
Feb 16, 2021Perceptive Advisors LLC13G/AOld format–––SEC
Feb 16, 2021Price T Rowe Associates Inc13G/AOld format–––SEC
Feb 12, 2021Avoro Capital Advisors LLC13G/AOld format–––SEC
Feb 10, 2021Vanguard Group Inc13G/AOld format–––SEC
Feb 1, 2021Franklin Resources Inc13G/AOld format–––SEC
Jan 29, 20219:57 AM ETBlackRock Inc.13G/AOld format–––SEC
Jan 11, 2021ARK Investment Management LLCSuperinvestorARK Invest13GOld format–New–SEC

Form 144: proposed insider sales

1 notice from officers, directors and other affiliates planning to sell Iovance Biotherapeutics, Inc. shares, newest first.

Form 144 notices for IOVA
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Nov 12, 20247:11 PM ETMaynard Ryan DDirector50.0K$503.1KNov 12, 2024Morgan Stanley Smith Barney LLC Executive ServicesSEC